Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL.
Foà R, Bassan R, Elia L, Piciocchi A, Soddu S, Messina M, Ferrara F, Lunghi M, Mulè A, Bonifacio M, Fracchiolla N, Salutari P, Fazi P, Guarini A, Rambaldi A, Chiaretti S. Foà R, et al. Among authors: lunghi m. J Clin Oncol. 2024 Mar 10;42(8):881-885. doi: 10.1200/JCO.23.01075. Epub 2023 Dec 21. J Clin Oncol. 2024. PMID: 38127722 Free PMC article.
Digital droplet PCR for T315I BCR::ABL1 KD mutation assessment in adult Ph-positive acute lymphoblastic leukemia with a minimal residual disease increase.
Cardinali D, Beldinanzi M, Ansuinelli M, Elia L, Della Starza I, Bellomarino V, Matarazzo M, Di Trani M, Cola M, Salutari P, Cedrone M, Bassan R, De Gobbi M, Della Porta MG, De Simone M, Alati C, Fracchiolla NS, Lunghi M, Intermesoli T, Cardinali V, Mulè A, Guarini A, Foà R, Chiaretti S. Cardinali D, et al. Among authors: lunghi m. Leuk Lymphoma. 2023 Nov-Dec;64(11):1884-1887. doi: 10.1080/10428194.2023.2235450. Epub 2023 Jul 15. Leuk Lymphoma. 2023. PMID: 37452789 No abstract available.
Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study.
Fracchiolla NS, Sciumè M, Papayannidis C, Vitale A, Chiaretti S, Annunziata M, Giglio F, Salutari P, Forghieri F, Lazzarotto D, Lunghi M, Imovilli A, Scappini B, Bonifacio M, Dargenio M, Gurrieri C, Todisco E, Defina M, Del Principe MI, Zappasodi P, Cerrano M, Santoro L, Tagliaferri E, Barozzi E, De Roberto P, Canzi M, Buzzatti E, Sartor C, Passamonti F, Foà R, Curti A. Fracchiolla NS, et al. Among authors: lunghi m. Cancers (Basel). 2023 Sep 19;15(18):4623. doi: 10.3390/cancers15184623. Cancers (Basel). 2023. PMID: 37760592 Free PMC article.
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan.
Malagola M, Iurlo A, Bucelli C, Abruzzese E, Bonifacio M, Stagno F, Binotto G, D'Adda M, Lunghi M, Crugnola M, Ferrari ML, Lunghi F, Castagnetti F, Rosti G, Lemoli RM, Sancetta R, Coppi MR, Corsetti MT, De Gobbi M, Romano A, Tiribelli M, Russo Rossi A, Russo S, Defina M, Farina M, Bernardi S, Butturini G, Pellizzeri S, Roccaro AM, Russo D. Malagola M, et al. Among authors: lunghi m. Clin Lymphoma Myeloma Leuk. 2024 May;24(5):323-331. doi: 10.1016/j.clml.2024.01.008. Epub 2024 Jan 25. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38369436 Free article. Clinical Trial.
Ponatinib alone or with chemo-immunotherapy in heavily pre-treated Philadelphia-like acute lymphoblastic leukemia: a CAMPUS ALL real-life study.
Kaiser F, Lunghi M, Cardinali D, Bellomarino V, Beldinanzi M, Starza ID, Malfona F, Basilico CM, Defina M, Mastaglio S, Giglio F, Lazzarotto D, Salutari P, Piccini M, Cardinali V, Pierini A, Fracchiolla NS, Di Biase F, Annunziata M, Di Trani M, Foa R, Chiaretti S. Kaiser F, et al. Among authors: lunghi m. Haematologica. 2024 Aug 1. doi: 10.3324/haematol.2024.285258. Online ahead of print. Haematologica. 2024. PMID: 39086308 Free article.
Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study.
Lazzarotto D, Cerrano M, Papayannidis C, Chiaretti S, Mosna F, Fracchiolla N, Zappasodi P, Imbergamo S, Del Principe MI, Lunghi M, Lussana F, Piccini M, Fumagalli M, Dargenio M, Salutari P, Forghieri F, Da Molin TG, Bonifacio M, Olivi M, Giglio F, Trappolini S, Leoncin M, Mule A, Delia M, Pasciolla C, Grimaldi F, Cambo B, Santoro L, Guolo F, Minetto P, Defina M, Chiusolo P, Fanin M, Mauro E, Aprile L, Mazzone C, Trastulli F, Ciccone M, De Gobbi M, Cignetti A, De Bellis E, Mancini V, Piciocchi A, Vignetti M, Marsili G, Starza ID, Fanin R, Luppi M, Ferrara F, Pizzolo G, Bassan R, Foa R, Candoni A. Lazzarotto D, et al. Among authors: lunghi m. Haematologica. 2024 Aug 15. doi: 10.3324/haematol.2024.285638. Online ahead of print. Haematologica. 2024. PMID: 39157875 Free article.
Prescription patterns of venetoclax in acute myeloid leukemia.
Ucciero A, Traversa G, Pisterna A, Cardinali V, Sciabolacci S, Poloni A, Capelli D, Gaidano G, Patriarca A, Lunghi M. Ucciero A, et al. Among authors: lunghi m. Hematol Oncol. 2024 Jul;42(4):e3298. doi: 10.1002/hon.3298. Hematol Oncol. 2024. PMID: 38989910 No abstract available.
Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study.
Geissler K, Koristek Z, Del Castillo TB, Novák J, Rodríguez-Macías G, Metzelder SK, Illes A, Mayer J, Arnan M, Keating MM, Krauter J, Lunghi M, Fracchiolla NS, Platzbecker U, Santini V, Sano Y, Oganesian A, Keer H, Lübbert M. Geissler K, et al. Among authors: lunghi m. Br J Haematol. 2024 Sep 23. doi: 10.1111/bjh.19741. Online ahead of print. Br J Haematol. 2024. PMID: 39313917
137 results